Table 5 MMT cohort biomarkers for each group at days 10 and 21
Target | Concentration (pg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|
Day 10 | Day 21 | |||||||
Vehicle control | 25 μL ASA | 50 μL ASA | FGF18 | Vehicle control | 25 μL ASA | 50 μL ASA | FGF18 | |
CINC-2 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 1.12 ± 0.48** |
Fractalkine | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 76.99 ± 39.24* |
GM-CSF | 2.18 ± 1.33 | 2.80 ± 1.64 | 20.68 ± 6.79* | 1.46 ± 0.69 | 27.50 ± 8.33 | 4.24 ± 1.51** | 17.91 ± 3.86 | 7.37 ± 1.47* |
IL-1β | NT | NT | NT | NT | 7.30 ± 3.25 | NT | 0.35 ± 0.35 | 0.00 ± 0.00* |
IL-2 | NT | NT | NT | NT | 54.34 ± 18.52 | NT | 234.60 ± 53.51^ | 1.84 ± 1.84 |
IL-4 | 0.26 ± 0.12 | 0.25 ± 0.16 | 0.45 ± 0.18 | 0.00 ± 0.00 | 0.17 ± 0.04 | 0.06 ± 0.02 | 0.20 ± 0.06 | 1.64 ± 0.53** |
IL-6 | NT | NT | NT | NT | 3.71 ± 1.45 | NT | 4.24 ± 2.00 | 27.72 ± 7.27** |
IL-10 | NT | NT | NT | NT | 20.10 ± 7.99 | NT | 78.67 ± 23.87* | 47.91 ± 17.14 |
LIX | 4.38 ± 1.71 | 2.08 ± 1.08 | 8.68 ± 1.73 | 34.90 ± 12.71** | 9.15 ± 2.03 | 4.37 ± 0.96 | 5.89 ± 1.16 | 152.00 ± 27.36‡ |
MCP-1 | NT | NT | NT | NT | 79.82 ± 11.36 | NT | 79.82 ± 12.25 | 759.90 ± 34.11‡ |
bNGF | 12.85 ± 2.53 | 17.69 ± 4.46 | 14.61 ± 3.41 | 56.44 ± 13.26^ | 11.09 ± 1.80 | 16.02 ± 1.38 | 17.17 ± 1.85 | 129.70 ± 16.95‡ |
VEGF | 151.40 ± 27.06 | 224.20 ± 36.66 | 162.1 ± 17.76 | 918.80 ± 131.30‡ | 119.80 ± 10.07 | 136.20 ± 17.09 | 173.40 ± 11.36 | 1234.00 ± 70.32‡ |